CLYM (Climb Bio) Forward Dividend Yield %: 0.00% (As of Jun. 25, 2026)


CLYM Climb Bio Inc CLYM
22 GF Score
Price $12.75
! 2 Warning Signs
View Full Analysis

What is Climb Bio Forward Dividend Yield %?

Climb Bio CLYM +3.83% 22 Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus rates CLYM with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 146 Biotechnology companies, Climb Bio ranks worse than 684930.82% on this metric.

As of today (2026-06-25), the Forward Annual Dividend Yield of Climb Bio is 0.00%.

As of today (2026-06-25), the Trailing Annual Dividend Yield of Climb Bio is 0.00%.

CLYM's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.495
* Ranked among companies with meaningful Forward Dividend Yield % only.

Climb Bio's Dividends per Share for the three months ended in Mar. 2026 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Climb Bio  (NAS:CLYM) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Climb Bio Forward Dividend Yield % Related Terms

CLYM vs ACRS, CABA, IMMX: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, Climb Bio's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Climb Bio Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Climb Bio's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Climb Bio's Forward Dividend Yield % falls into.


CLYM
22GF Score
Climb Bio Inc CLYM
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Climb Bio Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Climb Bio (CLYM) has a Forward Dividend Yield % of 0.00% as of Jun. 25, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Climb Bio and its competitors. According to the industry distribution chart, Climb Bio ranks #999999 out of 146 companies in the Biotechnology industry.
Is Climb Bio's Forward Dividend Yield % too high?
Climb Bio's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Climb Bio ranks #999999 out of 146 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Climb Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Climb Bio's Forward Dividend Yield % compare to ACRS and CABA?
According to the Biotechnology industry distribution chart, Climb Bio ranks #999999 out of 146 companies for Forward Dividend Yield %. This places Climb Bio in the lower half of its industry. The industry median Forward Dividend Yield % is 1.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.50, based on 146 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Climb Bio and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Climb Bio's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Climb Bio stock overvalued right now?
Climb Bio (CLYM) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Climb Bio's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Climb Bio (CLYM), the current Forward Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Climb Bio Business Description

Address 20 William Street, Suite 145, Wellesley Hills, MA, USA, 02481
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score

Get the complete analysis for CLYM

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.75
Price